Immuron Limited American Depositary Shares
Symbol: IMRN (NASDAQ)
Company Description:
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
- Today's Open: $2.25
- Today's High: $2.245
- Today's Low: $2.07
- Today's Volume: 45.20K
- Yesterday Close: $2.09
- Yesterday High: $2.22
- Yesterday Low: $2.06
- Yesterday Volume: 56.79K
- Last Min Volume: 10
- Last Min High: $2.24
- Last Min Low: $2.24
- Last Min VWAP: $2.24
- Name: Immuron Limited American Depositary Shares
- Website: https://www.immuron.com.au
- Listed Date: 2007-12-13
- Location: ,
- Market Status: Active
- CIK Number: 0001660046
- SIC Code:
- SIC description:
- Market Cap: $15.19M
- Round Lot: 100
- Outstanding Shares: 6.71M
- Asset Type: ADRC
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-23 | 6-K | View |
| 2025-10-21 | 6-K | View |
| 2025-10-21 | 6-K | View |
| 2025-10-20 | 6-K | View |
| 2025-10-17 | 6-K | View |
| 2025-10-14 | 6-K | View |
| 2025-10-10 | 6-K | View |
| 2025-10-08 | 6-K | View |
| 2025-10-03 | 424B5 | View |
| 2025-10-03 | 6-K | View |
| 2025-10-02 | 6-K | View |
| 2025-09-30 | 6-K | View |
| 2025-09-26 | 6-K | View |
| 2025-09-25 | 20-F | View |
| 2025-09-16 | 6-K | View |
| 2025-09-02 | 6-K | View |
| 2025-08-26 | 6-K | View |
| 2025-08-15 | 6-K | View |
| 2025-08-13 | 6-K | View |
| 2025-07-21 | 6-K | View |